reports
- Jesper Ingildsen
Accelerated launch of ODACTRA
ALK-Abello has announced that the FDA has completed the transfer of the tablet portfolio licences in North America (NA), and it plans to accelerate the launch of its HDM SLIT-tablet (ODACTRA) into Q4 2017 (from mid-2018). Accordingly, it has revised its full-year guidance to EBITDA of cDKK225–250m (previously cDKK300m) and free cash flow to cDKK-700m (previously cDKK-600m). We view this as a positive, and reiterate our BUY recommendation and DKK1,200 target price.
- Jesper Ingildsen
Accelerated launch of ODACTRA
ALK-Abello has announced that the FDA has completed the transfer of the tablet portfolio licences in North America (NA), and it plans to accelerate the launch of its HDM SLIT-tablet (ODACTRA) into Q4 2017 (from mid-2018). Accordingly, it has revised its full-year guidance to EBITDA of cDKK225–250m (previously cDKK300m) and free cash flow to cDKK-700m (previously cDKK-600m). We view this as a positive, and reiterate our BUY recommendation and DKK1,200 target price.
- Jesper Ingildsen
Accelerated launch of ODACTRA
ALK-Abello has announced that the FDA has completed the transfer of the tablet portfolio licences in North America (NA), and it plans to accelerate the launch of its HDM SLIT-tablet (ODACTRA) into Q4 2017 (from mid-2018). Accordingly, it has revised its full-year guidance to EBITDA of cDKK225–250m (previously cDKK300m) and free cash flow to cDKK-700m (previously cDKK-600m). We view this as a positive, and reiterate our BUY recommendation and DKK1,200 target price.
- Jesper Ingildsen
- Jesper Ingildsen
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.